物理性质
- 熔点32-38°C
- 沸点330 °C at 760 mmHg
- 密度1.46 g/mL at 25 °C(文献)
- PH:5.2-8.0 (50g/l, H2O, 25°C)(anhydrous substance)
- PSA:180.94
- LogP:-1.031 (est)
- 溶解性水: 1 M At 20 °c, Clear, Colorless
- 敏感性易潮解,在干燥环境中可直接失去结晶水成无水芒硝。芒硝易溶于水和甘油,溶于水后呈中性。当温度低于32.4 °C时,可以从饱和硫酸钠溶液中析出芒硝晶体。产于干涸盐湖的化学沉积物中,与石膏、石盐、泻利盐、无水芒硝等共生。
- 外观形态白色固体
- 储存条件储存在 +15°C to +25°C.
- 产品应用用于制造无水硫酸钠,钠盐,洗涤剂,无水颜料,印刷油墨,鞣革,纺织印染和染料. 制法:滩田法.将硝水放入人工滩田,经自然蒸发,冷冻,得十水硫酸钠. 包装:露天堆放. 储运注意事项:贮运时应防雨淋.
- 性质描述白色固体结晶或粉末.溶于水和甘油,不溶于乙醇.密度为 2.68克/厘米 3 .有吸湿性,在空气中易为一水盐.加热时易发生一系列同质多晶变化,于890°C时熔融.
专利信息
专利号:US-2025129021-A1
优先权日:2023-09-19
标 题:Small molecule protein synthesis modulators
发明人:GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I), Formula (V)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.
专利号:US-2003203915-A1
优先权日:2002-04-05
标题 :Nitric oxide donors, compositions and methods of use related applications
发明人:FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; LIN CHIA-EN; RANATUNGA RAMANI R; RICHARDSON STEWART K; WANG TIANSHENG; WANG WEIHENG; WEY SHIOW-JYI
权利人:FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; LIN CHIA-EN; RANATUNGA RAMANI R; RICHARDSON STEWART K; WANG TIANSHENG; WANG WEIHENG; WEY SHIOW-JYI
摘要:The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent. The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders and sexual dysfunctions. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The therapeutic agent can optionally be substituted with at least one NO and/or NO 2 group (i.e., nitrosylated and/or nitrosated). The invention also provides novel compositions and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.
专利号:US-5256552-A
优先权日:1988-02-08
标题 :Process for the production of optically active 2-hydroxy-4-phenylbutyric acid
发明人:MATSUYAMA AKINOBU; NIKAIDO TERUYUKI; KOBAYASHI YOSHINORI
权利人:DAICEL CHEM
摘要:2-Oxo-4-phenylbutyric acid is treated with a microorganism, which has been optionally treated, capable of asymmetrically reducing 2-oxo-4-phenylbutyric acid into either (R)-2-hydroxy-4-phenylbutyric acid or (S)-2-hydroxy-4-phenylbutyric acid, and the (R)-2-hydroxy-4-phenylbutyric acid or (S)-2-hydroxy-4-phenylbutyric acid thus produced is recovered to thereby give optically active 2-hydroxy-4-phenylbutyric acid. n The optically active 2-hydroxy-4-phenylbutyric acid is an important intermediate in the synthesis of various drugs such as a remedy for hypertension.
专利号:US-4995911-A
优先权日:1988-06-14
标 题:Process for recovering unreacted sucrose from reaction mixture in synthesis of sucrose fatty acid esters
发明人:MATSUMOTO SHUSAKU; HATAKAWA YOSHIO; NAKAJIMA AKIHIKO
权利人:DAI ICHI KOGYO SEIYAKU CO LTD
摘要:A process for recovering unreacted sucrose from a reaction mixture of sucrose and a fatty acid alkyl ester in an organic solvent as reaction medium in the presence of a catalyst in the production of a sucrose fatty acid ester which comprises adjusting the reaction mixture from which a part of the organic solvent as reaction medium may be previously removed and to which water is added, to a neutral pH region, adding a neutral salt and sucrose to the reaction mixture to precipitate the sucrose fatty acid ester, filtering off the precipitate, and bringing the filtrate into contact with a reverse osmosis membrane to recover the unreacted sucrose. According to the invention, unreacted sucrose can be easily recovered, while the sucrose fatty acid ester not contaminated with the organic solvent as reaction medium can be obtained from the reaction mixture without using an organic solvent for purification.
专利号:US-7442802-B2
优先权日:2002-06-27
标 题:Cyclooxygenase-2 selective inhibitors, compositions and methods of use
发明人:BANDARAGE UPUL K; EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; KHANAPURE SUBHASH P; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.
专利号:US-8487108-B2
优先权日:2005-11-14
标题 :Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors
发明人:BALDWIN JOHN J; CLAREMON DAVID A; TICE COLIN; CACATIAN SALVACION; DILLARD LAWRENCE W; ISHCHENKO ALEXEY V; YUAN JING; XU ZHENRONG; MCGEEHAN GERARD; SIMPSON ROBERT D; SINGH SURESH B; ZHAO WEI; FLAHERTY PATRICK T
权利人:BALDWIN JOHN J; CLAREMON DAVID A; TICE COLIN; CACATIAN SALVACION; DILLARD LAWRENCE W; ISHCHENKO ALEXEY V; YUAN JING; XU ZHENRONG; MCGEEHAN GERARD; SIMPSON ROBERT D; SINGH SURESH B; ZHAO WEI; FLAHERTY PATRICK T; VITAE PHARMACEUTICALS INC
摘要:The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.